Vivos Therapeutics

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Highlands Ranch, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q3 2022

Earnings data Q2 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vivos Therapeutics reports revenue decline but eyes growth through FDA clearances

Vivos Therapeutics reported a decline in revenue for Q1 2024 but showcased improved operating performance and cash flow management. The company is focused on revenue growth initiatives, strategic collaborations, and expanding product access to achieve cash flow positivity by late 2024 or early 2025. Challenges include revenue decline and the need to reduce dependency on dentistry channel.

Vivos Therapeutics reports robust Q2 earnings, eyes market expansion

Vivos Therapeutics delivered a strong Q2 2024 performance with revenue growth, improved margins, and cost management driving financial stability and operational efficiency.
The company's strategic initiatives, including the alliance with a sleep clinic and FDA clearances, position it well for market expansion and revenue enhancement.
While challenges in maintaining growth and managing costs persist, Vivos has opportunities to leverage its strengths in customer loyalty, financial stability, and market reach for sustainable growth.
By focusing on revenue optimization, cost control, and strategic partnerships, Vivos aims to enhance profitability, drive innovation, and capture new market opportunities.

Vivos Therapeutics reports revenue growth and strategic expansion plans

Vivos Therapeutics showed revenue growth and improved gross profit margins in Q3 2024. Despite challenges in net loss and cash burn, the company is optimistic about achieving positive cash flow and expanding its market presence through strategic alliances.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Littleton, CO.

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Kirk Huntsman - Chariman & CEO Brad Amman - CFO Conference Call Participants Scott Henry - Alliance Global Partners Lucas Ward - Ascendiant Capital Markets. Operator Good day, everyone, and welcome to the Vivos Therapeutics Third Quarter 2024 Earnings Conference Call.

Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript

Vivos Therapeutics (NASDAQ:VVOS), a medical technology targeting sleep issues such as obstructive sleep apnea (OSA) and snoring, had a strong third quarter marked by higher revenue and reduced operating expenses.  Revenue increased 17% year-over-year to $3.9 million compared to $3.3 million in the same period last year.

Vivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3

LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plans to release its third quarter 2024 financial results after market close on Thursday, November 14, 2024.

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics (NASDAQ:VVOS) announced that the American Medical Association (AMA) has granted new CPT codes for the company's Vivos CARE oral medical devices. Effective January 1, 2025, these codes will streamline insurance coverage and reimbursement for Vivos' devices, designed to treat obstructive sleep apnea (OSA) in both adults and children.

Vivos Therapeutics wins approval for streamlined insurance reimbursement for sleep apnea treatment

New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and Children New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and Children

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

Vivos Therapeutics (NASDAQ:VVOS) announced that it has entered into definitive purchase agreements with institutional investors to raise proceeds of $4.3 million through the issuance and sale of an aggregate of 1,363,812 shares at $3.15 each. The company said that no stock purchase warrants are being issued in this at-the-market offering.

Vivos Therapeutics raises $4.3 from institutional investors

Vivos Therapeutics (NASDAQ:VVOS) announced that it has received US Food and Drug Administration (FDA) approval to treat moderate to severe obstructive sleep apnea (OSA) in children aged 6 to 17 using its proprietary oral medical device. This non-invasive, orthodontic-based solution offers an alternative to traditional treatments like adenotonsillectomy, which may not always be effective long-term.

Vivos Therapeutics' oral device approved by FDA for pediatric sleep apnea treatment

Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Leap Therapeutics

Ocean Biomedical Inc

Biotech stocks are some of my favorite stocks to watch and invest in for a couple of reasons.

3 Trending Biotech Penny Stocks

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q2 2024 Earnings Conference Call August 14, 2024 5:00 PM ET Company Participants John Lee - Vivos' Executive Vice President of Marketing Kirk Huntsman - Chairman & Chief Executive Officer Brad Amman - Chief Financial Officer Conference Call Participants Do Kim - Water Tower Research Lucas Ward - Ascendiant Incorporated Operator Good day, everyone, and welcome to the Vivos Second Quarter 2024 Earnings Conference Call. [Operator Instructions] This conference is being recorded, and a replay of today's call will be available in Investor Relations section of Vivos' website and will be remaining posted there for the next 30 days.

Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript

Vivos Therapeutics (NASDAQ:VVOS) reported solid financial numbers for the second quarter of 2024 with a 19% increase in revenue. The company reported a revenue of $4.1 million compared to the $3.4 million reported in the same quarter of 2023, which the company said was primarily driven by increased sales of Vivos appliances and higher service revenue from Vivos Integrated Provider (VIP) enrollments.

Vivos Therapeutics boosts Q2 revenue, cuts operating losses amid new strategic partnerships

Revenue Increased 19% both Sequentially and Year over Year Operating Expenses Decreased 31%, Marking Eight Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today reported financial results and operating highlights for the second quarter and six months ended June 30, 2024.

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

LITTLETON, Colo., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plans to release its second quarter 2024 financial results after market close today, Wednesday, August 14, 2024.

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics (NASDAQ:VVOS) has announced positive results from a seven-month, multi-site pilot of its new provider-based marketing and distribution model. The medical technology firm on June 12, 2024, unveiled its new marketing and distribution model under which it seeks to drive revenue through partnerships with dentists and sleep treatment providers to offer patients with obstructive sleep apnea (OSA) a range of evidence-based treatment options, including Vivos' FDA-cleared CARE oral medical devices, oral appliances, and additive adjunctive therapies and methods.

Vivos Therapeutics reports positive results from pilot of provider-based model

8 Out of 10 Newly Diagnosed OSA Patients Choose Oral Appliance Therapy Over CPAP and Preferred Vivos' Flagship CARE Oral Medical Devices 5 to 1 Over Traditional Oral Appliances 8 Out of 10 Newly Diagnosed OSA Patients Choose Oral Appliance Therapy Over CPAP and Preferred Vivos' Flagship CARE Oral Medical Devices 5 to 1 Over Traditional Oral Appliances

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

Vivos Therapeutics (NASDAQ:VVOS) announced a strategic marketing and distribution alliance with a multi-center sleep testing and treatment operator in Colorado. In a statement, Vivos said that the alliance marks a shift in Vivos' approach to distributing its advanced obstructive sleep apnea (OSA) treatments.

Vivos Therapeutics announces strategic alliance and $7.5M investment

Alliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in Vivos' Marketing and Distribution Model Aimed at Enhancing Revenue Streams and Potential Profit

Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance

Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q1 2024 Results Conference Call May 14, 2024 5:00 PM ET Company Participants Julie Gannon - Investor Relations Officer Kirk Huntsman - Chairman & Chief Executive Officer Brad Amman - Chief Financial Officer Conference Call Participants Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone, and welcome to the Vivos Therapeutics First Quarter 2024 Earnings Conference Call. At this time, participants are in a listen-only mode.

Vivos Therapeutics, Inc. (VVOS) Q1 2024 Earnings Call Transcript

Vivos Therapeutics (NASDAQ:VVOS) told investors it continues to anticipate becoming cash flow positive from operations by the end of 2024 or the first quarter of 2025 as it successfully executes its cost-cutting initiatives and launches new strategic revenue initiative.  The company, which is developing and commercializing proprietary treatments for sleep-related breathing disorders including obstructive sleep apnea (OSA), said that during the first quarter its operating expenses decreased by 22% or $1.6 billion from the year-ago quarter.

Vivos Therapeutics reports first quarter cost savings, launches revenue-generating initiative

Vivos Expanding its Revenue Generating Initiatives As Operating Expenses Decrease 22%, Representing Seven Consecutive Quarters of Year Over Year Improvement Due to Successful Cost Cutting Initiatives

Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update

LITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plans to release its first quarter 2024 financial results after market close today, Tuesday, May 14, 2024.

Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics (NASDAQ:VVOS) CEO Kirk Huntsman expects to see more medical and dental professionals recommending its oral medical devices for obstructive sleep apnea (OSA) after they secured Medicare reimbursement approval.   The company announced earlier this week that its CARE oral medical devices, an alternative to continuous positive airway pressure (CPAP) for patients with OSA, have been approved for Medicare reimbursement by the Centers for Medicare and Medicaid Services (CMS).

Vivos Therapeutics expects increased adoption of oral medical devices following Medicare reimbursement approval

Vivos Therapeutics (NASDAQ:VVOS) announced that its CARE oral medical devices for obstructive sleep apnea (OSA) have been approved for Medicare reimbursement. The company said this milestone achievement will allow millions of Medicare beneficiaries coverage and reimbursement for allowable charges billable to Medicare.

Vivos Therapeutics CARE oral medical devices approved for Medicare reimbursement

Vivos Therapeutics (NASDAQ: VVOS ) stock is on the rise Tuesday after the medical technology company announced an update for its CARE oral medical devices. The big news here that has VVOS stockholders excited is full reimbursement for these devices through Medicare.

Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today?

First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea in Adults First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea in Adults

News for Vivos Therapeutics Stock (VVOS)